Noom LegitScript and Accreditation Status: What Women Need to Know Before Signing Up

Is Noom a Legitimate Company?

Noom is a real, operational wellness company founded in 2008 and headquartered in New York City. It is not a scam in the sense of vanishing with your money, but "legitimate" has layers, and women deserve a precise answer on each one.

The company operates a psychologically-grounded coaching app built around cognitive behavioral principles, and more recently it added Noom Med, a telehealth arm that can prescribe GLP-1 receptor agonists including semaglutide. Noom is incorporated, employs licensed clinicians, and has processed millions of subscriptions. None of that is in dispute.

What is in dispute: whether its accreditation credentials, billing practices, and clinical oversight meet the bar women should expect from a telehealth provider handling prescription weight-loss drugs.

What LegitScript Certification Actually Means

LegitScript is an independent certification body that evaluates online pharmacies and telehealth providers against standards including licensed prescribers, valid patient-provider relationships, prescription requirements, and legal pharmacy sourcing. Google, Meta, and most major ad platforms require LegitScript certification before allowing pharmaceutical advertising.

As of January 2025, Noom does not appear in LegitScript's public registry of certified telemedicine providers or certified pharmacies. This does not mean Noom is operating illegally. It means it has not completed or maintained LegitScript's third-party verification process. Women should weigh this against competitors in the GLP-1 telehealth space who do hold active certification.

BBB Rating and Complaint Patterns

The Better Business Bureau currently rates Noom a B-, a drop from earlier higher ratings. The BBB has logged more than 3,900 complaints against Noom in the past three years, with the dominant themes being:

• Automatic renewal charges after free trials
• Difficulty canceling subscriptions
• Refund denials despite cancellation requests within stated windows
• Inconsistent access to assigned health coaches

Billing complaints are not a clinical safety issue, but they matter. A service that frustrates you into staying subscribed is one you are less likely to engage with, and disengagement kills behavioral weight-loss outcomes.

Noom's GLP-1 Prescribing Arm (Noom Med): What Women Should Evaluate

Noom Med launched in 2023 to offer GLP-1 receptor agonist prescriptions, primarily oral semaglutide and, in some states, injectable semaglutide or compounded GLP-1 products. The clinical model works as follows: you complete an online intake, a licensed prescriber (MD, DO, or NP) reviews your history asynchronously, and if you qualify, a prescription is sent to a pharmacy.

GLP-1 receptor agonists are the most effective non-surgical weight-loss medications currently available, with semaglutide 2.4 mg producing an average ~15% body weight reduction over 68 weeks in the STEP 1 trial. That evidence base is real.

The clinical concerns center on what happens around that evidence.

Compounded Semaglutide: An FDA Warning Women Need to Read

During the semaglutide shortage, many telehealth companies, including some Noom Med partner pharmacies, have used compounded semaglutide from 503A or 503B compounding pharmacies. The FDA has explicitly stated that compounded semaglutide is not FDA-approved, has not been evaluated for safety and efficacy through FDA review, and that the agency has received reports of adverse events linked to compounded products, including dosing errors from incorrect units.

If Noom Med or any telehealth service offers you compounded semaglutide, ask explicitly: which 503B outsourcing facility is supplying it, and is it salt-form (semaglutide sodium or acetate) or base-form? Salt-form compounded semaglutide has not been demonstrated to be bioequivalent to brand-name Ozempic or Wegovy.

Asynchronous Care and Its Limits for Women

Noom Med's prescribing model is largely asynchronous: a questionnaire, a review, a prescription. This works for straightforward cases. It is less suited to women whose weight and metabolic health are shaped by conditions that require clinical dialogue.

Women with PCOS, for example, have insulin resistance as a central driver of weight gain, and GLP-1 therapy has meaningful benefits in this group beyond simple caloric reduction, but the dose titration and monitoring differ from standard obesity management. Women in perimenopause experience a visceral fat redistribution driven by estrogen decline that affects both drug response and cardiovascular risk framing. An online intake form rarely captures this nuance.

How Noom's Behavioral Coaching Model Holds Up for Women

The core Noom app, separate from Noom Med, is built around lessons in cognitive behavioral therapy, food psychology, and habit formation. The company's internal pilot data published in Scientific Reports reported that among 35,921 users who completed at least 16 weeks, 77.9% lost weight, with a mean loss of 7.3 kg. Average program completion in that dataset was 265 days.

That sounds encouraging. Several caveats matter.

First, this was an industry-sponsored, observational study with no control group. People who complete 265 days of any structured program lose weight. The counterfactual is unknown.

Second, the study population was not stratified by hormonal status, reproductive stage, or menstrual cycle phase. Weight loss in women is measurably affected by cyclic hormonal variation, with progesterone-dominant luteal phases associated with higher appetite and lower insulin sensitivity. Noom's app does not currently integrate menstrual cycle tracking in a clinically meaningful way.

Third, long-term maintenance data is thin. The CALERIE trial and other behavioral intervention studies show that most people regain a substantial portion of lost weight within two to three years without ongoing support.

What the Coaching Actually Looks Like

Noom pairs you with a goal specialist (a human coach) for brief daily check-ins, primarily via in-app messaging. Response times are variable. The coaching is not delivered by registered dietitians or licensed clinical social workers in most cases, and Noom has faced criticism for using undertrained coaches for the volume of users the platform carries.

If you are managing an eating disorder history, disordered eating patterns, or emotional eating rooted in significant psychological history, a behavioral app with a non-licensed coach is not a substitute for a registered dietitian or licensed therapist with eating-disorder training.

Life-Stage Breakdown: How Noom Fits (or Doesn't) at Different Points in a Woman's Life

Women's metabolic health is not static. The appropriateness of Noom's model shifts significantly across reproductive stages, and no competitor piece maps this directly. Here is a stage-by-stage assessment.

Reproductive Years (Ages ~18-40, Regular Cycles)

Noom's behavioral coaching model is most applicable here. Caloric awareness, habit formation, and GLP-1 therapy (when clinically indicated, BMI >27 with a comorbidity or BMI >30) have the strongest evidence base in this population.

Women in this group who are not using reliable contraception and are considering Noom Med's GLP-1 prescriptions need to know that semaglutide is contraindicated in pregnancy based on animal studies showing fetal harm. You should be using effective contraception throughout GLP-1 therapy.

Trying to Conceive (TTC)

GLP-1 therapy through Noom Med is not appropriate if you are actively trying to conceive. Semaglutide should be discontinued at least two months before attempting pregnancy based on its half-life and teratogenicity data in animal models. Noom's online intake does not prominently screen for TTC status.

The behavioral coaching component of Noom may offer some value during TTC for women who want to optimize pre-conception weight, but any caloric restriction protocol should be reviewed by your OB-GYN or reproductive endocrinologist before you begin.

Perimenopause (Typically Ages 45-55, Variable)

This is where Noom's generic model is most mismatched. Perimenopausal women face declining estrogen driving visceral adiposity, disrupted sleep (which independently drives weight gain), insulin resistance shifts, and mood changes that affect eating behavior. A calorie-counting app with behavioral nudges does not address the hormonal substrate.

If you are in perimenopause and struggling with weight gain that feels different from earlier in life, a conversation with a menopause-informed clinician about menopausal hormone therapy (MHT) is clinically relevant. The Menopause Society (NAMS) 2023 position statement notes that MHT does not cause weight gain and may attenuate the visceral fat accumulation associated with estrogen loss. Noom Med does not prescribe MHT.

Postpartum and Lactation

GLP-1 receptor agonists are not recommended during breastfeeding. Animal data shows semaglutide is present in rat milk, and human lactation transfer data is not available. The manufacturer recommends against use during breastfeeding. The behavioral coaching component of Noom carries no known lactation risk, but caloric restriction during breastfeeding requires careful management: the Academy of Nutrition and Dietetics recommends an additional 330-400 kcal/day above pre-pregnancy maintenance during exclusive breastfeeding, and aggressive deficit protocols may reduce milk supply.

Post-Menopause

GLP-1 therapy for post-menopausal weight management has a growing evidence base. The STEP 5 trial included women up to age 75 and showed sustained weight loss at two years. Noom Med's GLP-1 prescribing is technically available to post-menopausal women who meet criteria.

The key concern in this group: bone health. Rapid weight loss is associated with accelerated bone mineral density loss, and post-menopausal women already carry elevated fracture risk. Noom's platform does not include bone health monitoring or DEXA screening guidance.

Pregnancy and Lactation Safety: GLP-1 Drugs Through Noom Med

This section addresses semaglutide and other GLP-1 agonists that Noom Med may prescribe.

Pregnancy: Semaglutide (Wegovy, Ozempic, Rybelsus) carries an FDA label contraindication in pregnancy. Animal reproduction studies at human-equivalent doses showed fetal structural abnormalities and embryo death. Human data is very limited. The drug should be stopped at least two months before a planned pregnancy due to its approximately one-week half-life and the need for complete clearance. If you become pregnant while on semaglutide, stop the drug immediately and contact your OB-GYN.

Lactation: Human breast milk transfer data does not exist for semaglutide. Animal data shows transfer into rat milk. Given the unknown risk and the availability of alternative weight management approaches, semaglutide should not be used during breastfeeding.

Contraception requirement: Because GLP-1 agonists, including oral semaglutide, may alter absorption of oral contraceptives (particularly in the first few weeks of dose titration when nausea and delayed gastric emptying are most pronounced), ACOG recommends discussing backup contraception with your prescriber if you rely on oral contraceptive pills. A barrier method or IUD removes this concern entirely.

Who Noom Is and Is Not Right For

May Be a Reasonable Fit If You...

• Want structured behavioral coaching delivered via app at a lower cost than one-on-one dietitian sessions
• Meet BMI criteria for GLP-1 therapy (BMI >30, or BMI >27 with type 2 diabetes, hypertension, or dyslipidemia) and have no contraindications
• Are in your reproductive years with regular cycles and using reliable contraception
• Have no history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (both are contraindications to semaglutide)
• Have no active or prior eating disorder that warrants clinical-level behavioral support

Is Likely Not the Right Service If You...

• Are pregnant, planning pregnancy in the next two to three months, or breastfeeding (GLP-1 component is contraindicated; coaching alone may be insufficient)
• Are in perimenopause and need hormonal management as part of your weight strategy
• Have PCOS with significant insulin resistance requiring coordinated endocrine and reproductive care
• Have a personal or family history of medullary thyroid cancer or MEN2
• Need synchronous, clinician-led monitoring for complex metabolic conditions
• Have experienced disordered eating and need licensed eating-disorder support

Noom Complaints: What Real Users Report and What to Do

The most frequently cited complaints against Noom fall into two categories.

Billing and cancellation. The free-trial-to-paid-subscription pipeline has generated thousands of BBB complaints. Before entering payment information, screenshot the cancellation policy and trial end date. Cancel through the app and confirm via email. Several state attorneys general have received complaints about Noom's auto-renewal practices.

Coach quality and access. Users report delays of 24 hours or more in coach responses, coaches handling hundreds of clients simultaneously, and a lack of clinical credentials in coaches handling sensitive disclosures. If you are using Noom Med for GLP-1 prescriptions, your prescriber is a licensed clinician, but your behavioral coach is typically not.

One WomanRx reader and NP summarized it this way:

"The gap I see with platforms like Noom Med is that the prescribing is done by a licensed clinician, but the ongoing support sits with a health coach who may have no clinical training. For a woman in perimenopause who is also managing thyroid disease and PCOS, that support gap matters enormously. She needs a team, not an app." Sarah Chen, WHNP-BC, WomanRx Women's Health Editorial Board

What Independent Verification Looks Like and What to Ask Any Telehealth Provider

LegitScript certification is one benchmark, not the only one. When evaluating any telehealth weight-loss service, ask:

1. Are your prescribers licensed in my state, and can I verify their license number on my state medical board website?
2. Which pharmacy will fill my prescription? Is it a licensed retail pharmacy (e.g., CVS, Walgreens, a NABP-accredited mail-order pharmacy) or a compounding pharmacy?
3. If compounded, is the compounding pharmacy registered with the FDA as a 503B outsourcing facility?
4. What is your monitoring protocol for GLP-1 side effects including pancreatitis, gallbladder disease, and heart rate changes?
5. Do you offer any bone-density or metabolic lab monitoring?

Noom Med does include lab review in some states. Verify this for your specific plan before enrolling.

The Evidence Gap: What We Don't Know About Noom Specifically in Women

Women have been historically underrepresented in obesity clinical trials, and behavioral app research is even thinner on sex-stratified analysis. Noom's published data does not stratify outcomes by menstrual status, hormonal contraceptive use, menopausal status, or reproductive history. This matters because:

• Hormonal contraceptives affect weight, appetite, and insulin sensitivity in ways that interact with both behavioral and pharmacological weight-loss interventions
• Menopausal women have different metabolic set points and a different response profile to caloric restriction
• PCOS, present in an estimated 8-13% of reproductive-age women, creates an insulin-resistance-driven obesity phenotype that may respond differently to pure behavioral coaching

We do not have Noom-specific data stratified by any of these variables. What exists is the broader GLP-1 and behavioral coaching literature, which has been partially studied in women with PCOS and perimenopausal women, and the extrapolation is reasonable but not confirmed in Noom's specific app-plus-coaching model.